BRCA2 and Lynch syndrome: Of the 1474 patients who underwent genetic testing, PVs were identified in 123 individuals, including 76 actionable PVs (5.2%), of which 17 were in BRCA1 or BRCA2 and 11 were in Lynch syndrome–associated genes (eTable 4 in Supplement 2).